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The Efficacy of Glucosamine Sulfate in Osteoarthritis: Financial and Nonfinancial
Conflict of Interest
Jean-Yves Reginster
Glucosamine has attracted a lot of interest as a
specific drug for osteoarthritis (OA). Pharmacologic
treatment of the disease is in fact dominated by the use
of nonspecific analgesics or antiinflammatory agents,
including nonsteroidal antiinflammatory drugs
(NSAIDs) that have shown modest, although sound,
symptomatic efficacy over short-term treatment courses,
but no relevant effect during long-term use (1) and a
poor risk/benefit ratio (2). Conversely, glucosamine ap-
pears to be safe (3). In addition, well-conducted clinical
research with a particular form of glucosamine sulfate
has shown clinically relevant symptom modification over
medium-term treatment of knee OA (4). This symptom
modification is sustained for years, and there is an
intriguing suggestion of possible disease (structure)
modification (5,6). These long-term effects are particu-
larly relevant (7), given the chronic and progressive
nature of this degenerative joint disease.
Several reviews and meta-analyses have scruti-
nized the efficacy of glucosamine. At least 3 of these
have emerged as being worthy of attention: a most
important Cochrane Review first released in 2001 and
updated in 2005 (8), a meta-analysis from our group that
had the merit of being the first to include the long-term
trials of glucosamine sulfate (9), and finally, 2 meta-ana-
lyses from a group in Boston. The Boston group’s first
meta-analysis was published in 2000 (10), but its useful-
ness is limited because it was performed before all of the
most relevant trials with glucosamine. Vlad and cowork-
ers have now updated their meta-analysis, and it is
published in this issue of Arthritis & Rheumatism (11).
All these meta-analyses suggest the efficacy of at
least 1 particular formulation of glucosamine sulfate,
which is a prescription drug in Europe. Actually, the
recent European League Against Rheumatism practice
guidelines for knee OA assign to glucosamine sulfate the
highest level of evidence, 1A, and strength of the
recommendation, A, acknowledging the high quality of
the studies performed (12). In contrast, Vlad and co-
workers dismiss the quality of the most important glu-
cosamine sulfate trials, as well as the major differences
in glucosamine forms, products, dosages, and trial de-
signs, and support only a view of bias due to industry
involvement (11), a conclusion I find to be inaccurate
and misleading.
There are therefore 2 aspects of this issue that
deserve attention. The first is of course the actual role of
industry bias in clinical research, and the second is an
understanding of why the findings of the meta-analysis
by Vlad et al are of concern.
Industry involvement in clinical research
Industry involvement is usually a predictor of
more positive results. The research referenced by Vlad
et al is comprehensive in acknowledging this fact. How-
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ever, as noted in a recent editorial on cyclooxygenase 2
inhibitor programs (13), industry control of most aspects
of a study does not necessarily affect the credibility of
the results. There are several other plausible and legit-
imate reasons why industry participation may give re-
sults that are different from, and more positive than,
those of independent research. The first is the study
design. Pharmaceutical companies have experienced
clinical pharmacologists who can design trials that are
better suited to showing the efficacy of a certain drug
because they avoid the influence of confounders. This
sometimes has the drawback of limiting the use of the
drug to defined patient characteristics or clinical situa-
tions and should satisfy a demand from regulators or
academia that drugs not be used beyond the indica-
tions for which they were studied. On the other hand,
less carefully designed clinical research, not per-
formed by the industry, is more likely to have several
confounders and yield null results.
A second reason for different results in cases of
industry participation is quality. Pharmaceutical compa-
nies are obliged to follow the principles of Good Clinical
Practice (GCP), an international and scientific quality
standard for the design, conduct, performance, monitor-
ing, auditing, recording, analysis, and reporting of clini-
cal trials that provides public assurance that the clinical
trial data are credible (14). In addition, compliance with
GCP avoids confounders, but this standard is seldom
adhered to by investigators performing research outside
the industry, due to the lack of the enormous financial
and human resources required.
In their meta-analysis, Vlad et al deal with indus-
try participation in glucosamine trials as an undue
accident, since they only report that the substance is
classified as a dietary supplement in the US, and the
supplement industry is often blamed for poor product
quality and poor, if any, research. However, the authors
fail to remind the reader that glucosamine is approved as
a prescription drug in all European Union countries and
in more than 50 other countries worldwide, thanks to the
studies performed by Rottapharm (Monza, Italy) with a
particular form of glucosamine sulfate. As is the case
with any prescription drug, for glucosamine sulfate, the
most relevant clinical trials are those initiated by, par-
ticipated in, and funded by the pharmaceutical company
that has spent years and millions of dollars to study,
patent, and develop that particular compound or prod-
uct, with the numerous concomitant obligations required
by the regulatory authorities. While independent data
analysis of industry-supported studies is desirable (13),
more advanced solutions are difficult to achieve. In fact,
it is not clear who should fund and supervise the
organization, performance, and monitoring of studies
that are of primary interest to the industry. A new
constructive collaboration between academic medicine
and industry should be promoted, but articles such as
that by Vlad et al may serve to impede such mutually
beneficial efforts.
Heterogeneity and quality in OA/glucosamine trials
The argument of the Boston group is that there is
much heterogeneity among glucosamine trials, espe-
cially if there is industry participation, that disappears in
purported independent studies that, by the way, provide
null efficacy results. I find fault with 2 aspects of this
argument.
The first is that significant heterogeneity is com-
mon, if not the rule, in meta-analyses of drug trials in
OA, and it is usually dealt with by subgrouping the trials
for homogeneous characteristics. This happened, for
example, with viscosupplementation, and it was solved
by subgrouping for hyaluronic acid type (15); with
rofecoxib, it was solved by subgrouping by dose (16);
and, more generally, with NSAIDs, it was solved by
pooling by design characteristics (1). In order to do this,
one needs to perform a systematic review and appreciate
the differences among trials, but this was not done by
Vlad et al.
Second, it is obvious that studies with negative
results will never show heterogeneity, since, by defini-
tion, they will all concentrate around a very homoge-
neous null effect. The real problem is that a systematic
review should be able to show whether they had any
chance of showing any efficacy.
In this respect, we agree with Vlad and coworkers
on at least 1 conclusion, that 500 mg of glucosamine
hydrochloride 3 times a day does not seem to be
effective. We probably did not need a meta-analysis to
achieve such a conclusion, since this was very clear from
the results of the only 2 high-quality trials performed
with this form of glucosamine: the study by Houpt et al
(17) and the recent Glucosamine/Chondroitin Arthritis
Intervention Trial (GAIT) (18). In the editorial accom-
panying the GAIT report, Hochberg actually expressed
regret that the GAIT investigators had not used glu-
cosamine sulfate, in light of the results of the studies by
Rottapharm (19). The third trial of glucosamine hydro-
chloride cited by Vlad et al (i.e., the study by McAlindon
et al [20]) is not valid since it was designed for a different
purpose (21), and the protocol specifically prevented
assessment of the effectiveness of glucosamine. This is
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curious; we expect industry to strictly adhere to proto-
cols and several other quality standards, but the same
expectations and obligations are apparently not applied
to some independent research.
Quality and trial design issues should also be
considered when claiming that purported independent
trials of glucosamine sulfate also yielded null results
when compared with industry-sponsored studies. These
issues could be summarized for at least 3 studies.
The trial by Cibere et al (22) allocated 35% of
patients to 1,000 mg/day glucosamine, a dosage that is
one-third lower than the approved dosage of 1,500
mg/day. In addition, the randomization/withdrawal de-
sign used by those investigators is inadequate for drugs
for which a carryover effect is hypothesized, such as for
glucosamine (23); indeed, almost 60% of their patients
did not have disease flares during the 6 months following
the open-label glucosamine run-in period. In addition,
the study was underpowered (70 patients/group), and
there were severe imbalances in patient characteristics at
baseline (sex and disease severity) in favor of placebo.
The trial by Rindone et al (24) was severely underpow-
ered (50 patients/group); it enrolled only men, who by
the authors’ admission, were older, heavier, had disease
of longer duration, and had more severe radiographic
changes than those in any other glucosamine studies.
Fifty-seven percent of these patients were unresponsive
to NSAIDs/analgesics, which were continued through-
out the study. The trial by Hughes and Carr (25) was
small (40 patients/group), and its power was severely
challenged further by enrolling patients with all degrees
of severity of knee OA (including 20% patients with
intractable disease, with Kellgren/Lawrence grade 4
[26]), with more than half of the patients continuing
their NSAID/analgesic medication, with a strong pla-
cebo response.
Glucosamine formulations and dosages
Most importantly, all these studies with null
results used unknown formulations of the dietary sup-
plement glucosamine sulfate, and the inconsistency of
active ingredients in commercially available glucosamine
sulfate is well recognized (27). Moreover, there are
different molecular forms of glucosamine sulfate (28),
some of which cannot be used in pharmaceutical prep-
arations unless they are stabilized (e.g., as in forms
patented by Rottapharm [29]). Finally, all of them are
used at a dosage of 500 mg 3 times a day. As a global
result, their pharmacokinetic behavior (which has never
been studied) might be different from that of the
Rottapharm formulation.
Vlad et al mention the possibility that the Rot-
tapharm formulation might indeed be more efficacious
than the others. Moreover, a panel of experts recently
met and commented on the data that support this
hypothesis (30). These data include higher plasma con-
centrations of glucosamine with the Rottapharm prod-
uct (31) than with the product used in the GAIT (32,33),
as well as a strong correlation of these plasma concen-
trations with synovial fluid levels (34) in a range that is
effective in vitro in inhibiting interleukin-1–induced
gene expression (35). The latter mechanism (36) has
replaced an older hypothesis of direct stimulation of
glycosaminoglycan synthesis that may contribute only
marginally, if at all, to the overall effect (37), unless
through the availability of sulfate ions (38).
The apparent superior profile of the Rottapharm
product might also be due to the special once-a-day
formulation, as emphasized in the Glucosamine Unum
In Die [once a day] Efficacy (GUIDE) trial, recently
reported in Arthritis & Rheumatism (4), in which 1,500
mg of glucosamine sulfate once a day tended to be more



















Herrero-Beaumont et al, 2007 (4)§ 6 210 5/5 Adequate Lequesne index WOMAC score
Reginster et al, 2001 (5) 36 212 4/5¶ Adequate WOMAC score –
Pavelka et al, 2002 (6) 36 202 5/5 Adequate Lequesne index WOMAC score
* WOMAC  Western Ontario and McMaster Universities Osteoarthritis Index.
† According to the method of Rochon et al (39).
‡ Change from baseline.
§ The Glucosamine Unum In Die Efficacy (GUIDE) trial.
¶ As reported in the Cochrane Review, although all methods are appropriate and would yield a Jadad score (41) of 5/5.
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efficacious than acetaminophen. This possibility of a
different effect for different dose regimens was men-
tioned, but underestimated, by Vlad et al.
Principles for a sound systematic review and meta-
analysis of glucosamine sulfate trials
In their meta-analysis, Vlad et al state that they
were not able to explain or get rid of the persistent
heterogeneity in industry-funded trials. In fact, they
failed to apply the principles of a sound systematic
review to the meta-analysis, but instead, put together
different efficacy outcomes and trial designs by mixing
4-week studies with 3-year trials, intramuscular/
intraarticular administrations with oral ones, and low-
quality small studies reported in the early 1980s with
high-quality studies reported in 2007. One of their
analyses outlined a huge change in effect size with the
decade of publication; they labeled this change nonsig-
nificant, although it is clearly one of the most important
determinants of heterogeneity.
Vlad et al have used allocation concealment as an
indicator of trial quality. While this approach is appro-
priate, they selectively assigned an “intermediate” or
even “inadequate” label to some of the most important
Rottapharm trials by misusing, not by misinterpreting,
the method of Rochon et al (39), or by using data
published in an abstract for the GUIDE trial, although a
high-quality full-length report was about to be published
(4).
Industry-supported trials have the great advan-
tage of also being classified according to their “pivotal”
status (i.e., whether they are used as primary proof of
efficacy in the drug registration dossier given their
quality, or whether they should only be considered
“supportive” of the evidence). I asked Rottapharm
which placebo-controlled trials are now listed as pivotal
in their registration dossier. They identified the 2 long-
term trials performed by our group (5) and by Pavelka’s
group (6), as well as the recent GUIDE trial performed
by Herrero-Beaumont et al (4). I accessed the databases
of these studies and produced a meta-analysis of these
pivotal trials using the same methods as used by Vlad et
al. All 3 knee OA studies are recent, high-quality trials
(Table 1). The change in Lequesne index from baseline
was the primary symptom outcome in the Pavelka et al
(6) and GUIDE (4) trials. However, this outcome was
not assessed in the trial by Reginster et al (5). Table 2
shows the results for the Western Ontario and McMas-
ter Universities Osteoarthritis Index (WOMAC) (40)
total scores in all 3 trials. The change in WOMAC score
from baseline was the primary symptom end point in the
trial by Reginster et al, and it was assessed in the other
2 trials as the principal secondary outcome. The Le-
quesne index data are summarized in Table 3, together
with all WOMAC score results.
The results were extremely homogeneous (no
heterogeneity according to the I2 calculation), since
Table 2. Summary effect sizes (with 95% CIs) of WOMAC total scores (change from baseline) in the 3 Rottapharm-supported pivotal trials of












Herrero-Beaumont et al, 2007 (4)‡ 210 34 12.9 14.1 8.2 16.0 0.31 (0.04–0.58)
Reginster et al, 2001 (5) 212 34 229.6  347.5 101.0  458.4 0.32 (0.04–0.59)
Pavelka et al, 2002 (6) 202 32 8.0  8.7 4.9  8.2 0.37 (0.09–0.64)
Total 624 100 – – 0.33 (0.17–0.49)
* 95% CI  95% confidence interval; WOMAC  Western Ontario and McMaster Universities Osteoarthritis Index.
† Effect sizes 0.00 favor glucosamine sulfate.
‡ The Glucosamine Unum In Die Efficacy (GUIDE) trial.
Table 3. Pooled effect sizes and heterogeneity of symptom outcomes
in Rottapharm-supported pivotal trials of 1,500 mg of glucosamine
sulfate taken once a day for treatment of knee osteoarthritis*
Outcome
Effect size
(95% CI)† Heterogeneity, I2
WOMAC scale
Total 0.33 (0.17–0.49) 0.00
Pain 0.27 (0.12–0.43) 0.00
Function 0.33 (0.17–0.48) 0.00
Lequesne index‡ 0.38 (0.19–0.57) 0.00
* Includes studies by Herrero-Beaumont et al (4), Reginster et al (5),
and Pavelka et al (6). 95% CI 95% confidence interval; WOMAC
Western Ontario and McMaster Universities Osteoarthritis Index.
† Estimates and 95% CIs from fixed-model meta-analysis method,
using the pooled standard deviation in each study/outcome.
‡ Not assessed by Reginster et al (5).
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these studies enrolled patients with similar disease char-
acteristics who underwent medium/long-term courses of
treatment. The effect size was consistent across the
parameters, and it was 0.30 or slightly higher. This
effect is small to medium, but it is clinically valid
(0.20), and especially, it is of the same magnitude as
that commonly encountered with other OA treatments,
including NSAIDs (1). The major advantage of glu-
cosamine sulfate over NSAIDs is that the duration of the
effect ranges between 6 months and 3 years (i.e., it is not
limited to an average of 4–12 weeks as with common
symptomatic medications [1]), and it is therefore of
major clinical relevance in the OA treatment armamen-
tarium.
Scientists should exercise caution when interpret-
ing studies such as the one by Vlad and colleagues (11).
While potential financial conflict of interest by pharma-
ceutical companies should be thoroughly assessed, other
forms of conflict of interest by declared independent
investigators, including financial (e.g., grants) and non-
financial aspects, may be at least as much a cause for
concern.
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